Addus HomeCare Corp.

ADUS

Nasdaq; healthcare; SIC 8082, Services-Home Health Care Services; CIK 0001468328

C

middle fifth of 367 graded peers in healthcare

rank 159 of 367; percentile 43.2; sampling error 2.5 points; lower is stronger

A B C D E


C, the tortoise



Scoreboard


Profitability	C percentile 43.1
Solvency	C percentile 45.8
Growth and financing	C percentile 49.8
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $1.4B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: dilution, short runway, distress
Inputs computable	9 of 14
Graded from	filings received through Feb 24, 2026 264 days before the rescan; latest periodic filing 10-Q received Nov 4, 2026
Last close	$123.36 2026-11-13; market equity $2.3B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 24, 2026

Addus has been providing home care services since 1979. We operate three segments: personal care, hospice, and home health. Our services are principally provided in-home under agreements with federal, state and local government agencies, managed care organizations, commercial insurers and private individuals. Our consumers are predominantly "dual eligible," meaning they are eligible to receive both Medicare and Medicaid benefits. As of December 31, 2025, we provided services in 23 states through approximately 262 offices. For the year ended December 31, 2025, we served approximately 107,000 discrete consumers.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 43.1						
Gross profitability	32.1%	32.3%		46.2	365	2025-12-31
Return on invested capital	not computable	9.3%				


latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(1.1%)	(6.6%)	78.9	799	2025-12-31
Gross margin stability, five years	0.5 pts	2.8 pts	4.1	242	2025-12-31
Solvency, sleeve percentile 45.8					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	5.50	(0.31)	16.8	743	2025-12-31
Net debt to EBITDA	not computable	1.82x			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	1.80x	2.96x	74.8	825	2025-12-31
Growth and financing, sleeve percentile 49.8					
Revenue growth, three-year compound	14.4%	10.1%	41.0	411	2025-12-31
Free cash flow growth, three-year compound	2.3%	11.0%	68.1	95	2025-12-31
Reinvestment rate	6.5%	37.1%	64.1	104	2025-12-31
Asset growth, three years	15.3%	2.3%	26.2	693	2025-12-31
Net share issuance, one year	not computable	2.4%			
prior share count is 48 days earlier					

Among 367 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
154	Xeris Biopharma Holdings, Inc. (XERS)	41.8	B/C	
155	Envista Holdings Corp. (NVST)	42.1	B/C	
156	Nephros Inc. (NEPH)	42.3	B/C	fortress balance sheet
157	Sight Sciences, Inc. (SGHT)	42.6	C	fortress balance sheet
158	Immucell Corp. (ICCC)	42.9	C	
159	Addus HomeCare Corp. (ADUS)	43.2	C	
160	Repligen Corp. (RGEN)	43.4	C	late filer, fortress balance sheet
161	Davita Inc. (DVA)	43.7	C	
162	Ligand Pharmaceuticals Inc. (LGND)	44.0	C	
163	NovoCure Ltd. (NVCR)	44.3	C	fortress balance sheet
164	Shattuck Labs, Inc. (STTK)	44.5	C	dilution

What the price implies

at the 2026-11-13 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(5.4%)	(1.5%)	46
Distance from 52-week high	(3.9%)	(32.0%)	85
EBIT to enterprise value	6.3%	(1.8%)	85
Free cash flow yield	4.5%	(1.0%)	80
Book value to price	0.51	0.29	68

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Sales to price	0.62	0.29	71
Composite equity issuance, five years	16.3%	19.1%	47
Relative strength against the sector, log excess return	(0.22)	(0.18)	46

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	11 (10-Q received Nov 4, 2026)
Median daily dollar volume, 63 sessions	$23.1M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$461.9M	2025-12-31	2026-02-24	10-K	26-005352
2	assets	us-gaap:Assets	$1.4B	2025-12-31	2026-02-24	10-K	26-005352
3	operating income	us-gaap:OperatingIncomeLoss	$91.0M	2023-12-31	2026-02-24	10-K	26-005352
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$81.3M	2023-12-31	2026-02-24	10-K	26-005352
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$18.8M	2023-12-31	2026-02-24	10-K	26-005352
6	total debt	us-gaap:LongTermDebt	$124.1M	2023-12-31	2024-02-27	10-K	24-021284
7	book equity	us-gaap:StockholdersEquity	$706.7M	2023-12-31	2026-02-24	10-K	26-005352
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$64.8M	2023-12-31	2025-02-25	10-K	25-026747
9	total debt	us-gaap:LongTermDebt	$131.8M	2022-12-31	2024-02-27	10-K	24-021284
10	book equity	us-gaap:StockholdersEquity	$633.5M	2022-12-31	2026-02-24	10-K	26-005352
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$80.0M	2022-12-31	2024-02-27	10-K	24-021284
12	net income	us-gaap:NetIncomeLoss	$95.9M	2025-12-31	2026-02-24	10-K	26-005352
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$111.5M	2025-12-31	2026-02-24	10-K	26-005352
14	assets	us-gaap:Assets	$1.4B	2024-12-31	2026-02-24	10-K	26-005352
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.4B	2025-12-31	2026-02-24	10-K	26-005352
16	gross profit	us-gaap:GrossProfit	$375.0M	2024-12-31	2026-02-24	10-K	26-005352
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.2B	2024-12-31	2026-02-24	10-K	26-005352
18	gross profit	us-gaap:GrossProfit	$339.9M	2023-12-31	2026-02-24	10-K	26-005352
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.1B	2023-12-31	2026-02-24	10-K	26-005352
20	gross profit	us-gaap:GrossProfit	$299.7M	2022-12-31	2025-02-25	10-K	25-026747
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$951.1M	2022-12-31	2025-02-25	10-K	25-026747
22	gross profit	us-gaap:GrossProfit	$269.8M	2021-12-31	2024-02-27	10-K	24-021284
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$864.5M	2021-12-31	2024-02-27	10-K	24-021284
24	current assets	us-gaap:AssetsCurrent	$269.5M	2025-12-31	2026-02-24	10-K	26-005352
25	current liabilities	us-gaap:LiabilitiesCurrent	$149.5M	2025-12-31	2026-02-24	10-K	26-005352
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$472.3M	2025-12-31	2026-02-24	10-K	26-005352
27	operating income	us-gaap:OperatingIncomeLoss	$138.6M	2025-12-31	2026-02-24	10-K	26-005352

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

28	book equity	us-gaap:StockholdersEquity	$1.1B	2025-12-31	2026-02-24	10-K	26-005352
29	liabilities	us-gaap:Liabilities	$352.0M	2025-12-31	2026-02-24	10-K	26-005352
30	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$14.1M	2023-12-31	2026-02-24	10-K	26-005352
31	interest expense	us-gaap:InterestExpense	$11.1M	2023-12-31	2024-02-27	10-K	24-021284
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$7.7M	2025-12-31	2026-02-24	10-K	26-005352
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$116.4M	2024-12-31	2026-02-24	10-K	26-005352
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$6.0M	2024-12-31	2026-02-24	10-K	26-005352
35	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$112.2M	2023-12-31	2026-02-24	10-K	26-005352
36	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$9.5M	2023-12-31	2026-02-24	10-K	26-005352
37	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$105.1M	2022-12-31	2025-02-25	10-K	25-026747
38	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$8.3M	2022-12-31	2025-02-25	10-K	25-026747
39	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$16.4M	2025-12-31	2026-02-24	10-K	26-005352
40	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$127.4M	2025-12-31	2026-02-24	10-K	26-005352
41	income tax	us-gaap:IncomeTaxExpenseBenefit	$31.5M	2025-12-31	2026-02-24	10-K	26-005352
42	current assets	us-gaap:AssetsCurrent	$260.4M	2024-12-31	2026-02-24	10-K	26-005352
43	current liabilities	us-gaap:LiabilitiesCurrent	$155.9M	2024-12-31	2026-02-24	10-K	26-005352
44	assets	us-gaap:Assets	$1.0B	2023-12-31	2025-02-25	10-K	25-026747
45	assets	us-gaap:Assets	$938.0M	2022-12-31	2024-02-27	10-K	24-021284
46	shares outstanding	dei:EntityCommonStockSharesOutstanding	18,518,271	2026-02-17	2026-02-24	10-K	26-005352
47	shares outstanding	dei:EntityCommonStockSharesOutstanding	18,643,615	2025-12-31	2026-03-12	10-K/A	26-007982

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.